GITNUXSOFTWARE REVIEW
Biotechnology & PharmaceuticalsTop 10 Best Biomarker Testing Services of 2026
Editorial roundup comparing biomarker testing services, including Labcorp, ARUP Laboratories, and Myriad Genetics, to help shortlist fit for decisions.
How we ranked these tools
Vendors set the topic, but our editors set the inclusion criteria and the evaluation framework before research starts.
AI search agents find sources, extract figures with provenance, and aggregate written reviews. They also transcribe video reviews and podcasts.
Framework: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page. This does not influence our reviews. Editorial policy
ARUP Laboratories is the best overall pick for clinical programs that need dependable, lab-driven biomarker testing because its governance emphasizes controlled specimen handling and standardized result reporting artifacts, whereas Labcorp is a strong alternative for organizations scaling high-volume biomarker workflows with centralized accession and electronic reporting consistency.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
ARUP Laboratories
Lab governance built around controlled specimen handling and standardized result reporting artifacts across complex biomarker assays.
Best for: Fits when clinical programs need dependable, lab-driven biomarker testing with strict operational control.
Labcorp
Editor pickCentralized accession and electronic reporting workflows designed for high-volume biomarker result delivery across networks.
Best for: Fits when organizations need scalable biomarker testing with strong specimen handling and reporting consistency.
Myriad Genetics
Editor pickCurated variant interpretation package designed to produce decision-ready outputs from tumor genomic profiling.
Best for: Fits when oncology programs need managed genomic biomarker testing with interpretation artifacts for review.
Comparison Table
ARUP Laboratories
specialistNational reference laboratory affiliated with the University of Utah providing specialized biomarker testing.
Lab governance built around controlled specimen handling and standardized result reporting artifacts across complex biomarker assays.
ARUP Laboratories runs biomarker testing with strong emphasis on lab operations for complex, specimen-driven assays. The workflow focus includes molecular testing and pathology-adjacent, clinical-program use where chain of custody and consistent result interpretation matter. Clinical teams benefit from controlled turnarounds and reporting artifacts that support repeatable methodologies across multiple program sites.
The main tradeoff is that ARUP’s value is strongest when testing needs align with lab-centered operations rather than when an organization wants to self-direct assay development. ARUP fits best when biomarker testing must integrate cleanly into clinical reporting processes that require rigorous documentation and traceable laboratory outputs.
- +Strong execution of high-complexity biomarker assays with documented lab processes
- +Clear ordering and result workflows that fit clinical chain-of-custody requirements
- +Broad menu coverage across multiple biomarker test modalities
- +Consistent reporting artifacts that reduce downstream interpretation friction
- –Integration effort is higher for organizations needing heavy automation or custom mappings
- –Some biomarker programs require tighter pre-analytic coordination to avoid reruns
Hospital pathology and lab teams
Complex molecular biomarker turnaround support
Consistent lab reporting artifacts
Multi-site oncology programs
Standardize biomarker assay methodology
Uniform assay execution
Best for: Fits when clinical programs need dependable, lab-driven biomarker testing with strict operational control.
Labcorp
enterprise_vendorGlobal clinical laboratory providing biomarker testing services including companion diagnostics and specialty molecular assays.
Centralized accession and electronic reporting workflows designed for high-volume biomarker result delivery across networks.
Labcorp supports biomarker testing programs that require consistent analytical execution across multiple specimen types and sites, with documented laboratory processes behind each assay workflow. The provider is a fit for organizations that need high-throughput processing with controlled turnaround from accession to reporting, rather than only bespoke assay design. Coverage includes common clinical assay modalities and pathology-adjacent workflows used in diagnostic and companion settings, which reduces the need to stitch multiple vendors.
A tradeoff is that deeper workflow integration depends on the buyer’s data and ordering environment, so API-driven automation may require governance work at the integration layer. Labcorp fits situations where a pharmaceutical or healthcare network already has a standardized ordering model and wants laboratory execution plus result delivery that downstream teams can ingest with fewer manual steps.
- +Large lab network supports consistent biomarker workflows at scale
- +End-to-end execution from specimen accession to electronic result delivery
- +Assay portfolio breadth reduces the need for multiple lab partners
- +Repeatable laboratory processes support stable batch throughput
- –Integration automation depends on buyer systems and data ingestion design
- –Assay fit requires early coordination on specimen and method constraints
- –Program timelines can hinge on local onboarding and workflow alignment
- –Limited self-serve configuration versus tightly managed laboratory projects
Clinical operations teams
Order-to-result biomarker testing workflow
Fewer manual result reconciliations
Translational research groups
Predictive biomarker panel execution
More reliable cross-cohort comparisons
Show 2 more scenarios
Companion diagnostic programs
Patient stratification assay delivery
Faster clinical decision support
Coordinates laboratory execution and structured result outputs used for treatment decisions.
Bioinformatics and data teams
Downstream ingestion of lab outputs
Lower integration rework
Receives reporting artifacts that can be mapped into interpretation and review systems.
Best for: Fits when organizations need scalable biomarker testing with strong specimen handling and reporting consistency.
Myriad Genetics
specialistMolecular diagnostic company providing hereditary cancer and pharmacogenomic biomarker testing.
Curated variant interpretation package designed to produce decision-ready outputs from tumor genomic profiling.
Myriad Genetics delivers clinical biomarker testing built around comprehensive tumor profiling and companion diagnostic style workflows. Core capabilities include NGS-based genomic testing and curated variant interpretation workflows that support decision-relevant outputs for oncology studies and care.
The service experience centers on specimen intake, laboratory processing, and electronic reporting that route results into downstream clinical or research review. Operational fit is strongest for organizations that need managed testing with standardized interpretive artifacts rather than self-administered assay development.
- +Curated variant interpretation workflow supports consistent decision review
- +Tumor profiling coverage aligns with common oncology biomarker needs
- +Laboratory-to-report workflow reduces manual transcription and review errors
- +Managed testing model reduces internal assay validation burden
- –Turnaround and specimen handling expectations require tight site coordination
- –Less suited for labs seeking fully self-directed laboratory-developed test workflows
- –Workflow integration depth can depend on interface requirements and mapping effort
- –Limited public detail on automation and API-driven provisioning
Oncology study teams
Tumor profiling with interpretive outputs
Decision-ready variant calls
Clinical research coordinators
Managed testing with standardized artifacts
Standardized interpretation artifacts
Show 1 more scenario
Precision oncology groups
Companion-diagnostic style biomarker workflows
Structured molecular evidence
Produces comprehensive molecular results designed for structured clinical and research interpretation.
Best for: Fits when oncology programs need managed genomic biomarker testing with interpretation artifacts for review.
Natera
specialistCell-free DNA testing company providing molecular biomarker tests across oncology, reproductive health, and organ transplant.
Liquid biopsy testing workflows optimized for longitudinal ctDNA biomarker monitoring with structured electronic outputs.
Natera is a biomarker testing service built around clinical-grade molecular testing workflows that support oncology and inherited disease use cases. Its core differentiation is a production pipeline designed for liquid biopsy centered assays and targeted molecular outputs that feed downstream decision-making.
- +Liquid biopsy focused workflows built for ctDNA derived biomarker outputs
- +Production operations emphasize end to end specimen to result traceability
- +Molecular assay outputs support longitudinal monitoring use patterns
- +Report artifacts are structured for downstream clinical information systems
- –Integration depth depends on site specific ordering and result routing setup
- –Assay menu breadth may not match multi modality labs that want broad tissue coverage
Health system molecular teams
Liquid biopsy biomarker testing pipeline
Stable electronic result traceability
Oncology practices
Targeted molecular outputs for decisions
More actionable biomarker outputs
Show 1 more scenario
Lab informatics groups
Integrate assay results into systems
Lower integration friction
Provides consistent electronic reporting designed for ordering systems that require standardized artifacts.
Best for: Fits when oncology programs need ctDNA enabled biomarker reporting with strong specimen traceability.
Quest Diagnostics
enterprise_vendorClinical laboratory offering diagnostic and molecular biomarker testing services across oncology, cardiology, and infectious disease.
Specimen chain of custody plus electronic laboratory reporting workflows designed for enterprise health system operations.
Quest Diagnostics differentiates itself through enterprise-scale laboratory operations and broad clinical test catalog breadth, which supports biomarker testing across many therapeutic areas. Its biomarker workflows center on specimen chain of custody and high-throughput lab processing, which can reduce handoff friction for health systems that already standardize ordering and receiving.
- +Enterprise laboratory scale supports high specimen throughput across geographies
- +Specimen chain of custody processes reduce sample handoff risk
- +Electronic laboratory reporting fits existing ordering and results workflows
- +Wide clinical test catalog supports consistent biomarker ordering practices
- –Assay scope and turnaround depend on site and method availability
- –Automation and API details are not exposed in a way that enables self-serve integration planning
- –Variant interpretation workflows require tighter local governance than some competitors
- –Ordering models can be less flexible for niche research pipelines
Large health systems
High-throughput biomarker testing operations
Reduced handoff friction
Multidisciplinary oncology clinics
Assay mix across molecular and immuno methods
Broader method coverage
Show 1 more scenario
Enterprise lab reporting teams
Integrate biomarker results into ELR
Consistent ELR integration
Fits clinical ordering and electronic lab reporting processes used by health systems.
Best for: Fits when health systems need standardized biomarker testing with established ordering and electronic results integration.
Foundation Medicine
specialistMolecular information company providing comprehensive genomic profiling tests for cancer biomarker analysis.
Knowledge-rich, treatment-focused variant interpretation that ties genomic results to oncology decision context.
Foundation Medicine is a clinical biomarker testing service built around tumor genomic profiling and curated interpretation for oncology decision-making. The core capability centers on extracting DNA from tumor tissue or blood and running a panel-based diagnostic biomarker assay with standardized reporting.
- +Panel-based tumor profiling with treatment-relevant reporting context
- +Interprets variants through a curated knowledge framework for oncology decisions
- +Supports tissue and blood workflows for broader specimen availability
- +Standardized report outputs help reduce interpretation drift across teams
- –Turnaround depends on specimen readiness and collection-to-lab logistics
- –Clinical utility varies by cancer type and available evidence for targets
- –Integration depth relies on how the receiving system maps structured fields
- –Automation and API coverage is narrower than lab vendors offering direct EHR push
Oncology tumor boards
Curated tumor genomic biomarker profiling
More consistent treatment discussions
Clinical trial coordinators
Tissue or blood biomarker assay outputs
Trial-ready genomic results
Show 1 more scenario
Translational research teams
Integrate curated biomarker findings
Higher data governance consistency
Strengthens governance with specimen traceability and structured report outputs for research pipelines.
Best for: Fits when oncology teams need consistent panel-based genomic results and interpretive standardization.
Guardant Health
specialistPrecision oncology company specializing in liquid biopsy biomarker tests for cancer detection and management.
Guardant’s ctDNA-first testing workflow is built for repeated monitoring using blood specimens rather than tissue sampling.
Guardant Health performs liquid biopsy testing that profiles circulating tumor DNA from blood specimens for clinically actionable genomic variants. Core capabilities center on targeted ctDNA assays that support variant detection workflows and downstream clinical interpretation for oncology decision-making.
- +Liquid biopsy workflow tailored to ctDNA collection and variant calling pipelines
- +Clinical reports emphasize actionable variant summaries for oncology teams
- +Assay design supports longitudinal monitoring use cases from repeated blood draws
- +Operational process supports specimen chain of custody through end-to-end logistics
- –Blood-only testing can miss tumor-local alterations that require tissue context
- –Integration effort increases when systems need custom mappings to report fields
Oncology care teams
Blood-based ctDNA variant detection
Actionable variant findings
Genomic medicine operations
Integrate biomarker reports into systems
Faster clinical review
Show 1 more scenario
Follow-up and survivorship clinicians
Post-treatment biomarker evidence
Additional recurrence monitoring evidence
Provides blood-based biomarker results to support recurrence surveillance considerations after therapy.
Best for: Fits when oncology teams prioritize blood-based genomic profiling and recurring monitoring cycles.
Exact Sciences
specialistCancer screening and diagnostic company providing molecular biomarker-based detection tests.
Diagnostic-pathway execution for oncology biomarker testing tied to Exact Sciences’ colorectal testing operations.
Exact Sciences delivers biomarker testing tied to oncology diagnostics, with laboratory workflows built around clinically oriented specimen handling and assay execution. The service centers on its established colorectal cancer diagnostics portfolio and expands into broader biomarker needs through its lab operations and test menu approach.
- +Oncology-focused test menu aligned to real clinical diagnostic adoption
- +Operational maturity in high-volume lab execution and specimen processing
- +Electronic laboratory reporting built to fit clinical ordering workflows
- +Integrated coordination between sample intake and downstream result delivery
- –Less suited to highly customized biomarker assays beyond core workflows
- –Integration depth for advanced automation needs may require vendor mediation
- –API and provisioning surface is less transparent than for purely software-first labs
- –Methodological extensibility is narrower than research-focused biomarker providers
Screening providers
Blood-based cancer screening pathway
Non-tissue screening result
Cancer researchers
Biomarker cohort research using ctDNA
Cohort-ready molecular data
Show 2 more scenarios
Oncology follow-up teams
Recurrence monitoring with blood testing
Molecular recurrence support
Enables post-treatment biomarker testing to add molecular evidence for surveillance decisions.
Multi-site oncology networks
Outsource liquid biopsy biomarker testing
Provider-managed genomic testing
Outsources assay execution and reporting when sites lack internal capacity for blood-based workflows.
Best for: Fits when oncology programs want clinically grounded lab execution and reporting without heavy custom assay work.
Ambry Genetics
specialistGenetic testing laboratory offering hereditary cancer and rare disease biomarker testing services.
Structured clinical reporting built around controlled interpretation workflows and repeatable case processing.
Ambry Genetics provides biomarker testing that centers on genomic variant detection and clinical reporting for oncology use cases that require consistent interpretation and documentation. The operational flow typically begins with specimen chain of custody, proceeds through sequencing or laboratory assay execution, and ends with structured report outputs for clinician review. For teams that need repeatable case handling, the service includes administrative steps for test selection, accessioning, and result release workflows.
- +NGS-centric oncology testing workflow tied to standardized interpretation outputs
- +Specimen chain-of-custody and accessioning steps built into routine case handling
- +Documented analytical and reporting processes suitable for regulated clinical operations
- +Clear separation of ordering, lab processing, and result release stages
- –Integration depth varies by engagement, limiting turnkey API-style deployments
- –Custom mapping of report fields into internal schemas can add analyst effort
Oncology clinical operations
Routine biomarker testing for treatment selection
More consistent result handoffs
Companion diagnostic teams
Program testing across sites
Lower variability in outputs
Show 2 more scenarios
Molecular pathology labs
Outsourced NGS turnaround capacity
Improved testing availability
External sequencing and interpretation reduce local throughput constraints while maintaining traceability.
Regulated clinical research groups
Biomarker program operations
More auditable operational flow
Case workflows support controlled result release and predictable reporting content for monitoring.
Best for: Fits when oncology biomarker programs need managed interpretation consistency and disciplined specimen traceability.
Mayo Clinic Laboratories
enterprise_vendorReference laboratory offering specialized biomarker and esoteric testing services developed at Mayo Clinic.
Clinical laboratory reporting and interpretive guidance designed to support oncology decision-making workflows.
Mayo Clinic Laboratories supports biomarker testing through laboratory-developed and specialty assays that can be ordered as discrete tests in a clinical care pathway. The service is aligned to operational needs like specimen acceptance rules, documented handling, and electronic reporting that reduces rework for care teams. The lab network approach can help institutions reduce vendor fragmentation when multiple biomarker types are ordered through the same clinical laboratory channel.
- +Clinical-lab operating model supports consistent specimen handling and reporting
- +Broad oncology-focused assay menu supports multiple biomarker decision points
- +Interpretive context reduces back-and-forth between labs and clinical teams
- +Established laboratory governance supports standardized assay delivery
- –Limited evidence of deep automation and provisioning tooling for external systems
- –Assay execution remains centered on the lab workflow, not external orchestration
- –Integration depth depends on existing ordering and results pipelines
Hospital oncology teams
Order serial biomarker tests
Fewer delays in treatment updates
Molecular diagnostics labs
Validate and adopt external reference testing
Broader patient coverage
Show 2 more scenarios
Clinical research operations
Run biomarker testing for trials
Cleaner documentation for submissions
Trial staff use defined specimen intake and reporting to support protocol endpoints.
Precision medicine coordinators
Support predictive biomarker workflows
More consistent decision support
Ordering teams manage specimens and interpretive results for therapy selection discussions.
Best for: Fits when healthcare programs need consistent biomarker testing and interpretation under established lab governance.
Conclusion
After evaluating 10 biomarker testing, ARUP Laboratories stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
Frequently Asked Questions About Biomarker Testing
How do Labcorp and Quest Diagnostics differ in specimen chain of custody handling for high-volume biomarker testing?
Which service providers are built around liquid biopsy workflows for circulating tumor DNA monitoring?
How do Ambry Genetics and Foundation Medicine operationalize variant interpretation for clinical reporting?
When do centralized lab execution models from Labcorp, ARUP Laboratories, and Mayo Clinic Laboratories matter most?
What breaks if a lab program needs bespoke biomarker panels outside Exact Sciences’ core diagnostic pathways?
How do Myriad Genetics and Guardant Health differ in aligning genomic outputs to companion-diagnostic style decision support?
Which providers offer interpretation guidance designed for oncology decision workflows rather than raw assay results?
How do onboarding and data ingestion workflows typically differ between providers that integrate into existing EHR processes and those centered on specimen case intake?
What security and access controls are commonly addressed during integration, and where do they show up operationally?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
How to Choose the Right Biomarker Testing
Options differ most in how reliably biomarker testing results stand up to real samples, and how consistently the workflow reproduces those results. Watch the labels for limit of detection, specimen chain of custody, and audit log.
Limit of detection and measurable range
Why it matters
Limit of detection and measurable range control whether low-abundance signals still produce usable calls. That matters when samples are weak, diluted, or near the clinical decision boundary.
How to check
Ask for an example report that includes the lowest quantifiable level and a span of measured values. In the demo, load a sample with low signal and confirm the output includes whether results fall inside the measurable range.
Result calling with clear quantification
Why it matters
Result calling with clear quantification reduces ambiguity between “detected,” “not detected,” and borderline results. It also helps teams compare runs when they change reagents or instrumentation.
How to check
Request a sample output showing numeric values, qualitative calls, and what happens at the boundary. Then run the same sample file twice (or with two provided replicates) and confirm the call behavior stays consistent.
Specimen chain of custody tracking
Why it matters
Specimen chain of custody tracking is critical when the sample handling path affects biomarker integrity. It also prevents mix-ups that can invalidate clinical interpretation.
How to check
Look for a workflow screen that records specimen receipt, location, and transfer events. During the demo, try a re-label or re-routing scenario and confirm the history remains linked to the correct specimen ID.
Automation and API for batch workflows
Why it matters
Automation and API for batch workflows reduce transcription errors and shorten turnaround time for high-volume testing. They also help labs run consistent pipelines across multiple instruments and batches.
How to check
Ask how the tool triggers processing for new runs and how you can submit work for queued specimens. In the demo, review an example integration plan: inputs, status updates, and what the API returns for each run.
Audit log and run traceability
Why it matters
Audit log and run traceability make it possible to reconstruct what changed in a run and why. That matters for troubleshooting, internal review, and repeat testing decisions.
How to check
Create a test order in the demo, then change a setting or re-run processing. Confirm the audit log captures who changed what, when, and which output fields were affected.
Export formats for reporting handoff
Why it matters
Export formats for reporting handoff determine whether results can move cleanly into existing reporting flows. If the output is inconsistent, teams spend time reformatting and risk errors.
How to check
Request a sample export package and verify the fields match the on-screen report. On the demo, export once from the same run and compare two files for stable identifiers and consistent metadata.
Red flags
- Results show numbers but don’t explain detection boundaries clearly
- Specimen tracking history breaks when specimens are re-routed or relabeled
- Audit logs miss changes to run settings or output values
Fit by situation
- If we handle low-signal specimens often, prioritize limit of detection and measurable range.
- If we run batch testing across shifts, prioritize automation and API for batch workflows.
- If we need repeatability under review, prioritize audit log and run traceability.
Funding and competing interests
This study was co-funded by several of the vendors assessed in it. No single vendor funded it. Funders could propose the market studied.
They had no role in selecting vendors, setting or weighting criteria, analysing data or drawing conclusions, and they received the same factual-accuracy check as every other vendor assessed.
Market definition, inclusion rules and criteria weights were fixed by an editor before research began and did not change afterwards. Editorial process →
- Service review · 2026 · Biotechnology PharmaceuticalsBiomarker
- Service review · 2026 · Biotechnology PharmaceuticalsBiological Testing
- Service review · 2026 · Biotechnology PharmaceuticalsBiomarker Assay
- Review · 2026 · Biotechnology PharmaceuticalsGenetic Testing Software
- Review · 2026 · Biotechnology PharmaceuticalsDrug And Alcohol Testing Software
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
Biotechnology & Pharmaceuticals alternatives
See side-by-side comparisons of biotechnology & pharmaceuticals tools and pick the right one for your stack.
Compare biotechnology & pharmaceuticals tools→